NIH Locks Down Meeting on Early-Life HIV Research Funding
Published Date: 3/20/2025
Notice
Summary
The National Institute of Allergy and Infectious Diseases is holding a closed meeting on April 24, 2025, to review grant applications focused on early-life HIV immunity research. This meeting affects researchers applying for funding and keeps sensitive information private. The decisions made could impact future funding and scientific progress in fighting HIV.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
Clinical Trials Excluded from U01 Funding
The MIEL funding opportunity is a U01 mechanism where clinical trials are not allowed (listed as "U01 Clinical Trial Not Allowed"). If you are a researcher planning to propose a clinical trial, you cannot use this U01 solicitation for that work.
Closed Grant Review Protects Applicants' Privacy
The National Institute of Allergy and Infectious Diseases will hold a closed meeting on April 24, 2025 to review grant applications for the Mechanisms of Inducing HIV Immunity in Early Life (MIEL) U01 program. The meeting is closed under 5 U.S.C. 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, patentable material, and personal information of applicants.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in